Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults.

Blood pressure is a heritable determinant of cardiovascular disease (CVD) risk. Recent genome-wide association studies have identified several single-nucleotide polymorphisms (SNPs) associated with blood pressure, including rs1378942 in the c-Src tyrosine kinase (CSK) gene. Fish oil supplementation provides inconsistent protection from CVD, which may reflect genetic variation. We investigated the effect of rs1378942 genotype interaction with fish oil dosage on blood pressure measurements in the MARINA (Modulation of Atherosclerosis Risk by Increasing doses of N-3 fatty Acids) study, a parallel, double-blind, controlled trial in 367 participants randomly assigned to receive treatment with 0.45, 0.9, and 1.8 g/d eicosapentaenoic acid [EPA (20:5n-3)] and docosahexaenoic acid [DHA (22:6n-3)] (1.51:1) or an olive oil placebo for 12 mo. A total of 310 participants were genotyped. There were no significant associations with blood pressure measures at baseline; however, the interaction between genotype and treatment was a significant determinant of systolic blood pressure (SBP) (P = 0.010), diastolic blood pressure (DBP) (P = 0.037), and mean arterial blood pressure (MABP) (P = 0.014). After the 1.8 g/d dose, noncarriers of the rs1378942 variant allele showed significantly lower SBP (P = 0.010), DBP (P = 0.016), and MABP (P = 0.032) at follow-up, adjusted for baseline values, than did carriers. We found no evidence of SNP genotype association with endothelial function (brachial artery diameter and flow-mediated dilatation), arterial stiffness (carotid-femoral pulse wave velocity and digital volume pulse), and resting heart rate. A high intake of EPA and DHA could help protect noncarriers but not carriers of the risk allele. Dietary recommendations to reduce blood pressure in the general population may not necessarily benefit those most at risk. This trial was registered at controlled-trials.com as ISRCTN66664610.

[1]  W. Hall,et al.  Effect of low doses of long chain n-3 polyunsaturated fatty acids on sleep-time heart rate variability: A randomized, controlled trial , 2013, International journal of cardiology.

[2]  W. Hall,et al.  Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement[S] , 2013, Journal of Lipid Research.

[3]  J. Critchley,et al.  A systematic review of fish-oil supplements for the prevention and treatment of hypertension , 2013, European journal of preventive cardiology.

[4]  E. Ntzani,et al.  Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. , 2012, JAMA.

[5]  H. Allayee,et al.  Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans. , 2012, The Journal of nutrition.

[6]  S. Yusuf,et al.  n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. , 2012, The New England journal of medicine.

[7]  P. Pérez-Martínez,et al.  Long chain omega-3 fatty acids and cardiovascular disease: a systematic review , 2012, British Journal of Nutrition.

[8]  D. Mozaffarian,et al.  Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. , 2011, Journal of the American College of Cardiology.

[9]  W. Hall,et al.  Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. , 2011, The American journal of clinical nutrition.

[10]  Christian Gieger,et al.  Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure , 2011, Nature Genetics.

[11]  Tom R. Gaunt,et al.  Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk , 2011, Nature.

[12]  D. Levy,et al.  Discovery and replication of novel blood pressure genetic loci in the Women's Genome Health Study , 2011, Journal of hypertension.

[13]  J. Geleijnse,et al.  n-3 fatty acids and cardiovascular events after myocardial infarction. , 2010, The New England journal of medicine.

[14]  T. Ogihara,et al.  Blood Pressure and Hypertension Are Associated With 7 Loci in the Japanese Population , 2010, Circulation.

[15]  B. Han,et al.  Genetic variations in ATP2B1, CSK, ARSG and CSMD1 loci are related to blood pressure and/or hypertension in two Korean cohorts , 2010, Journal of Human Hypertension.

[16]  A. Minihane.  Fatty acid-genotype interactions and cardiovascular risk. , 2010, Prostaglandins, leukotrienes, and essential fatty acids.

[17]  Paolo Palatini,et al.  CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension , 2009, Journal of hypertension.

[18]  P. O’Reilly,et al.  Faculty Opinions recommendation of Genome-wide association study identifies eight loci associated with blood pressure. , 2009 .

[19]  Andrew D. Johnson,et al.  Genome-wide association study of blood pressure and hypertension , 2009, Nature Genetics.

[20]  M. Vohl,et al.  Effect of the PPAR-Alpha L162V Polymorphism on the Cardiovascular Disease Risk Factor in Response to n–3 Polyunsaturated Fatty Acids , 2008, Lifestyle Genomics.

[21]  A. Gunes,et al.  Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. , 2008, Pharmacogenomics.

[22]  D. Nebert,et al.  The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis , 2006, Nature Reviews Cancer.

[23]  A. El-Sohemy,et al.  Coffee, CYP1A2 genotype, and risk of myocardial infarction. , 2006, JAMA.

[24]  Bryan Williams,et al.  Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials , 2006, Journal of hypertension.

[25]  P. Calder.  n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. , 2004, Clinical science.

[26]  M. S. Ali,et al.  The critical role of c-Src and the Shc/Grb2/ERK2 signaling pathway in angiotensin II-dependent VSMC proliferation. , 2003, Experimental cell research.

[27]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[28]  D. Grobbee,et al.  Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials , 2002, Journal of hypertension.

[29]  P. Cole,et al.  Csk, a critical link of g protein signals to actin cytoskeletal reorganization. , 2002, Developmental cell.

[30]  E. Schiffrin,et al.  Src Is an Important Mediator of Extracellular Signal–Regulated Kinase 1/2–Dependent Growth Signaling by Angiotensin II in Smooth Muscle Cells From Resistance Arteries of Hypertensive Patients , 2001, Hypertension.

[31]  J. Brockmöller,et al.  Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.

[32]  F. Valtorta,et al.  Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. , 1996, The Journal of clinical investigation.

[33]  F. Sacks,et al.  Does Fish Oil Lower Blood Pressure? A Meta‐Analysis of Controlled Trials , 1993, Circulation.

[34]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.